Lymphoma Trial, Recruiting NCT07065344 Sponsor: AstraZeneca Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT07065344
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL).
  • For Group 1: People with a confirmed DLBCL diagnosis for whom the treating doctor has determined that starting treatment is appropriate.
  • For Group 2: People with a confirmed DLBCL diagnosis whose cancer has not responded to, or has come back after, at least one previous treatment.
  • People who are willing to sign a consent form showing they understand what the study involves and what will be required of them.

Who may not be able to join:

  • People for whom the treating doctor has determined that treatment is not appropriate for any reason.
  • People who currently have another active cancer in addition to DLBCL.
  • People who are currently taking part in another clinical trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
23 July 2025
Est. completion
31 January 2027

Where this trial is recruiting

🇪🇬 Egypt Iraq 🇯🇴 Jordan Kuwait Morocco Oman Qatar 🇸🇦 Saudi Arabia Turkey (Türkiye) 🇦🇪 United Arab Emirates

Primary endpoints

To describe the treatment patterns for the first line and subsequent therapies for DLBCL patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov